Orchid Cellmark's Q4 Revenues Rise 21 Percent on Forensics Testing Services | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported fourth-quarter revenue growth of 21 percent, driven by its forensic testing services in the UK and US.

The Princeton, NJ-based firm had total revenues of $15.7 million for the three-month period ended Dec. 31, compared to $13 million for the fourth quarter of 2008. Its service revenues rose to $14.9 million from $13 million year over year, led by forensic testing in the UK and US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."